Treating HER 2 positive metastatic breast cancer without chemotherapy?

WASHINGTON DC—Patients with metastatic breast cancer who are HER-2 positive could potentially be treated with the anti-HER-2 conjugated drug, trastuzumab-emtansine (T-DM1), alone — without needing to add chemotherapy. This prediction was made at the American Association for Cancer Research annual conference by Dr Jose Baselga Physician in Chief at New York’s Memorial Sloan-Kettering Cancer Center on the basis of data the EMILIA study (which led to the approval of this agent in the USA in 2013). He gave Peter Goodwin details about the effectiveness of this new agent in the presence of PI-3 kinase mutations.